Gastroesophageal Reflux Disease Therapeutics Market Analysis: Key Insights on Growth Rates, Trends, and Major Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the gastroesophageal reflux disease therapeutics market size evolved in recent years?
There has been a consistent enlargement in the market size of gastroesophageal reflux disease therapeutics in the recent past. The market is estimated to escalate from $5.93 billion in 2024 to $6.14 billion in 2025, portraying a compound annual growth rate (CAGR) of 3.6%. This growth during the historical period can be linked to shifts in lifestyle and eating habits, an aging populace, expanded awareness and diagnosis, prevalent stressful lifestyles, and a surge in obesity rates.
What are the predictions for the gastroesophageal reflux disease therapeutics market size in the coming years?
There is an anticipation of substantial advancement in the gastroesophageal reflux disease therapeutics market in the coming years. The market size is projected to increase to $7.89 billion by 2029, with a compound annual growth rate (CAGR) of 6.5%. The surge in the upcoming period can be tied to an increase in demand for innovative treatments, growth in the elderly population, tailored medical procedures, emphasis on non-drug interventions, and the arrival of biologics and novel therapies. Noteworthy tendencies for the predicted period include substitute therapies, mind-body practices, extensive research on gut health, introduction of patient-tailored care models, targeted promotional strategies for GERD awareness, and integration of digital health tools.
Get your gastroesophageal reflux disease therapeutics market report here!
What key factors are fueling the growth of the gastroesophageal reflux disease therapeutics market?
The escalation of gastroesophageal reflux disease is anticipated to fuel the expansion of the therapeutics market for the same condition. Characterized by the reverse flow of stomach acid into the esophagus, gastroesophageal reflux disease is a chronic ailment that can cause symptoms like heartburn, regurgitation, and possible complications. Therapeutics for this disease work by managing and reducing the symptoms of acid reflux through pH neutralization in the gut, controlling inflammation and enhancing esophageal function. To illustrate, a piece published by WebMed, a U.S. based online health news producer, claimed in September 2022 that over 60 million American adults experience heartburn at least once in a month and over 15 million suffer daily. Additionally, statistics circulated by the National Library of Medicine, an American federal medical library, in July 2022 revealed GERD to be one of the most commonly diagnosed digestive illnesses in the United States, prevalent in 20% of the population. This reportedly results in significant economic burden due to direct and indirect costs and negatively impacts quality of life. Consequently, the increasing prevalence of gastroesophageal reflux disease is anticipated to stimulate the gastroesophageal reflux disease therapeutics market’s growth.
How is the global gastroesophageal reflux disease therapeutics market divided into key segments?
The gastroesophageal reflux disease therapeutics market covered in this report is segmented –
1) By Type: Branded, Generic
2) By Drug Class: Antacids, Proton Pump Inhibitors, Histamine Blockers, Pro-Kinetic Agents, Other Drugs Class
3) By Distribution Channel: Hospital Pharmacy, Drug Stores, General Stores, Super markets
4) By Application: Crohn’s Disease, Gastroesophageal Reflux Disease (GERD), Ulcerative Colitis
Subsegments:
1) By Branded: Proton Pump Inhibitors (PPIs), H2-Receptor Antagonists, Antacids, Coating Agents
2) By Generic: Generic Proton Pump Inhibitors (PPIs), Generic H2-Receptor Antagonists, Generic Antacids, Generic Coating Agents
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12058&type=smp
Who are the key firms paving the way for growth in the gastroesophageal reflux disease therapeutics market?
Major companies operating in the gastroesophageal reflux disease therapeutics market include Pfizer Inc., Johnson and Johnson, Novartis AG, Sanofi S.A., AstraZeneca plc, Medtronic PLC, GlaxoSmithKline plc, Eisai Co. Ltd., Takeda Pharmaceutical Company Limited, bioMerieux SA, Teva Pharmaceutical Industries, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC, CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co. Ltd, Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Camber Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., EndoGastric Solutions, RaQualia Pharma Inc, TWi Pharmaceuticals Inc., Astellas Pharma Inc., SFJ Pharmaceuticals Group, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited
Which trends are expected to transform the gastroesophageal reflux disease therapeutics market?
Product advancements are the latest trend catching attention in the gastroesophageal reflux disease therapeutics market. Large-scale firms in this market are directing their focus towards revolutionary medicines in order to maintain their market dominance. For example, Phathom Pharmaceuticals, a biopharmaceutical organization based in the US, introduced VOQUEZNA (vonoprazan), a potassium-competitive acid blocker, in November 2023. This drug was approved for the treatment and upkeep of all degrees of erosive esophagitis, as well as to relieve heartburn linked with erosive and non-erosive GERD. Clinical studies exhibited substantial results, revealing a healing rate of 93% in patients prescribed with the 20 mg dosage, in comparison to 85% for the conventional proton pump inhibitor (PPI) lansoprazole.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12058
What regions are contributing significantly to the growth of the gastroesophageal reflux disease therapeutics market?
North America was the largest region in the gastroesophageal reflux disease therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroesophageal reflux disease therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Real-Time Location Systems (RTLS) Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/real-time-location-systems-global-market-report
Wireless Intercom Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/wireless-intercom-global-market-report
Commercial Services Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/commercial-services-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
